Geulah Livshits
Stock Analyst at Chardan Capital
(0)
# 4842
Out of 5,356 analysts
219
Total ratings
30.11%
Success rate
-22.68%
Average return
Main Sectors:
Top Industries:
Name | Action | PT | Current | % Upside | Ratings | Updated | |
---|---|---|---|---|---|---|---|
TSHA Taysha Gene Therapie... | Maintains: Strong Buy | 7 9 | 2.9 | 210.34% | 13 | May 29, 2025 | |
RCKT Rocket Pharmaceutica... | Maintains: Buy | 46 17 | 2.97 | 472.39% | 18 | May 28, 2025 | |
PRME Prime Medicine | Maintains: Buy | 16 12 | 1.61 | 645.34% | 5 | May 19, 2025 | |
SLDB Solid Biosciences | Maintains: Buy | 16 15 | 4.57 | 228.23% | 7 | May 19, 2025 | |
IPSC Century Therapeutics | Maintains: Buy | 7 6 | 0.62 | 867.74% | 6 | May 16, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 13 12 | 1.77 | 577.97% | 6 | May 15, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 22 20 | 3.82 | 423.56% | 9 | May 13, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 28 25 | 4.15 | 502.41% | 9 | May 9, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 30 25 | 1.95 | 1182.05% | 12 | May 9, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 68 68 | 8.14 | 735.38% | 14 | May 9, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 9 9 | 0.6 | 1400% | 11 | May 9, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 219 219 | 135.63 | 61.47% | 10 | May 7, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 84 82 | 40.96 | 100.2% | 13 | May 7, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 13 13 | 2.24 | 480.36% | 11 | May 6, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 12 12 | 3.74 | 220.86% | 8 | May 2, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 50 | 24.35 | 105.34% | 1 | Apr 9, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 7 6 | 0.43 | 1295.35% | 4 | Mar 4, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 3 | Jan 30, 2025 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 10 | Dec 13, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 11 6 | n/a | n/a | 5 | Apr 5, 2024 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 41 41 | 5.87 | 598.47% | 4 | Aug 11, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 28 25 | 6.18 | 304.53% | 2 | Mar 23, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Reiterates: Buy | 12 | 2.34 | 412.82% | 4 | Mar 22, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 30 25 | n/a | n/a | 4 | Mar 13, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 191 208 | 26.99 | 670.66% | 7 | Jan 18, 2023 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 160 40 | n/a | n/a | 3 | Dec 1, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 15 16 | 1.71 | 835.67% | 4 | Nov 15, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 4 3 | 6.68 | -62.57% | 5 | Aug 22, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 450 270 | n/a | n/a | 2 | Feb 22, 2022 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 100 90 | 9.26 | 871.92% | 1 | Nov 3, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 6 4 | 3.58 | 11.73% | 3 | Nov 3, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 20 | n/a | n/a | 1 | Oct 1, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Buy | 660 600 | 0.05 | 1199900% | 2 | Aug 13, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 50 30 | 2.77 | 983.03% | 1 | Jul 23, 2021 | |
XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Buy | 18 | 9.33 | 92.93% | 1 | Oct 27, 2020 |